Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... EDISON, N.J. , March 5, 2015  ContraVir ... company focused on the development and commercialization of targeted ... the 27 th Annual ROTH Conference, to be ... CA. James Sapirstein , ... Company,s business during his live presentation and will be ...
(Date:3/5/2015)... March 5, 2015 According to ... by Product (Systems and Disposables), by Type (Invasive, Minimally ... Home and Ambulatory Sites) - Analysis & Global Forecast ... is expected to reach $1,107.4 Million by 2019 from ... at a CAGR of 4.5% during the forecast period. ...
(Date:3/5/2015)... Denmark , March 5, 2015 ... that applies its innovative TransCon technology to address ... present two posters at the ENDO 2015 conference ... The posters will be presented on Thursday, March ... is being held from 1:00pm-3:00pm PST, and are ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4Ascendis Pharma to Present at ENDO 2015 2
... Worldwide, MENLO PARK, Calif., Nov. 15 ... global Phase III clinical program to,evaluate the efficacy ... program, which includes the COGENT-1 and COGENT-2 trials, ... in the United States, Canada,Europe and South America. ...
... Calif., Nov. 15 BiPar,Sciences, Inc., a privately ... it has initiated a Phase 2 study of ... breast,cancer that do not express the estrogen, progesterone ... Phase 2 trial in this indication-which,represents a major ...
Cached Medicine Technology:Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:3/5/2015)... Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ) filed ... strokes and other serious cardiovascular events due to their ... forward in the federal multidistrict litigation now underway in ... a Case Management Order issued on March 3rd, the ... master pleadings in the proceeding. Among other things, the ...
(Date:3/5/2015)... 2015 On March 2, 2015, NBC ... on the Rise, Plastic Surgeons Say,” that comments on ... for Aesthetic Plastic Surgery and the American ... a year-over-year doubling of surgical butt augmentations performed in ... the article, this increase can be attributed to the ...
(Date:3/5/2015)... HMP Communications Holdings , ... education, announced today its acquisition of the ... medical conference designed for health care providers dedicated ... amputation due to vascular disorders. The 5-year-old ... publications and CME activities across therapeutic fields such ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... 2015 Leading nutritional supplement provider ... Sports Festival and Arnold Fitness EXPO in ... will host a display booth featuring free samples of ... its highly-popular, class-leading fat burner Synedrex. The company will ... that utilize its top-of-the-line supplements and miniature action figures ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2
... test by using EEG can predict whether a person ... by Leslie S. Prichep of the New York University School ... 44 patients and followed these people for a decade. The ... would develop dementia. ,Dementia is a brain disorder that causes ...
... research from the National Institute of Diabetes and Digestive and ... shown stabalisation of annual increases from 5 to 10 ... there is still a dramatic racial disparity. , ... than 1 percent since 1999, compared to an average 5 ...
... cancer vaccine trial against Melanoma which is a type ... vaccine developed by Antigenics.// The vaccine trial of Oncophage ... the required statistically significance results compared to prolongation in ... any better results compared to other cancer treatments. ...
... a near-pandemic condition that threatens millions with loss of ... atherosclerotic plaque in the arteries outside your heart.// Stem ... blood vessels and grow new ones thus restoring blood ... Ltd, a private, multinational company focuses on using stem ...
... inflammation according to scientists. Inflammation has a role to ... cardiovascular disease, diabetes, obesity, Alzheimer’s besides infections//. , ... said: “Practically every common disease involves an inflammation component,” ... Research (SFBR) in San Antonio., ,“So the discovery ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
Cached Medicine News:Health News:US Kidney Failure Rates show Stabilization After 20-Year Climb 2Health News:Tennis elbow not new among cricketers, say experts 2
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... four models in proven halogen technology and ... find the right solution for every application: ... combination of two or three mobile lamps ... an on/off switch on the lamp housing, ...
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
Medicine Products: